The pharmaceutical sector was valued at US$ 33 billion in 2017. The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015–20 to reach US$ 55 billion.
The GST is assumed to add 1.5 to 2 per cent to the GDP, which will surely affect the overall growth of Indian healthcare industry in the long run, say market experts.
In line with its strategy to grow inorganically, Torrent Pharmaceuticals Ltd is close to sealing a deal to acquire the dermatology venture of Mumbai based Encore group.
